US00484M7002 - Common Stock
ACORDA THERAPEUTICS INC
NASDAQ:ACOR (3/28/2024, 8:00:00 PM)
13.211
+1.3 (+10.92%)
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 111 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
ACORDA THERAPEUTICS INC
Two Blue Hill Plaza
Pearl River NEW YORK 10502
P: 19143474300
CEO: Ron Cohen
Employees: 111
Website: https://www.acorda.com/
Acorda Therapeutics announced it will regain global commercialization rights to FAMPYRA, a treatment for multiple sclerosis, following the termination of...
Here you can normally see the latest stock twits on ACOR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: